Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin Combination Therapy for Salvage Invasive Aspergillosis
NCT00076869Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2003
- Primary completion
- Sep 2004
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
A Phase 2 trial of caspofungin in invasive aspergillosis (IA), sponsored by Merck & Co.. Started Jan 2003; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT00076869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076869.